Price History

Hover for the daily close. The dotted line marks the period open.

Compare VOGX with… →

VOGX Key Statistics

As of Sep 4, 2026

Trading

Open: $32.12
Previous Close: $32.15
Day's Range: 31.63–34.00
52-Week Range: 12.95–35.50
Volume: 89.60K

Valuation

Market Cap: $471.35M
P/E Ratio: unprofitable
EPS (ttm): −0.11

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$1.45M
Profit margin: 0.00%
Shares Outstanding: 14.86M

Dividend and dates

Avg Volume: 258.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VOGX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$1.45M	—
2024	$0.00	−$2.20M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$1.44M	−$1.45M	—
2024	$0.00	—	−$2.30M	−$2.20M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VOGX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	VOGX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

Jones Trading Initiates Coverage On Vogenx with Buy Rating, Announces Price Target of $55
Benzinga2026-09-01

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vogenx, Inc. (VOGX) at $471.35M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 4 employees.

Over the past 52 weeks the price has ranged from $12.95 to $35.50. VOGX last closed at $31.73 on September 4, 2026. That is −$0.42 (−1.31%) against the previous close. The latest close sits 145.02% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $1.45M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.11.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for VOGX.

So far in 2026 the price is +144.08%.

Peer Comparison

Vogenx, Inc. (VOGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Vogenx, Inc.	VOGX	$471.35M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Vogenx, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Vogenx, Inc.

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Visit website →

Vogenx, Inc. (VOGX) Stock Analysis